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Background
Bipolar Disorder is a disabling and often chronic condi-
tion. While at least one third of the time patients are
depressed, they do not always respond well to conven-
tional mood stabilizers. Attempts to treat them with anti-
depressants can provoke a switch to mania or increase the
cycling pattern. With increasing number of reports sug-
gesting that atypical antipsychotics may offer therapeutic
benefits, this study examines the long-term role of
Quetiapine, added on the usual treatment in patients with
Bipolar Depression.
Materials and methods
An open label trial to assess the long-term response of
patients with bipolar depression to Quetiapine added to
their usual treatment. Inclusion criteria were Bipolar Dis-
order type 1 or 2 as defined by DSM-IV, age over 18, cur-
rently depressed (HAM-D > 18), no change of
antidepressants for at least 3 weeks. Quetiapine was added
open label and the dose attempted to reach at least 300
mg per day, but lower doses were allowed, if clinically
appropriate. Outcome measures were HAM-D, YMRS,
CGI and AIMS at base and then monthly for twelve
months.
Results
Nineteen patients were enrolled in this study, 6 males and
13 females. Seven patients completed the full twelve
months. Data for 17 patients (Last Observation Carried
Forward, LOCF) at twelve months: HAM-D21 reduced
from 27.2 to 12.7, and CGI from 4.7 to 2.7. Only two
patients discontinued due to side effects.
Discussion
Quetiapine seems to be effective and well tolerated in
patients with Bipolar Depression when added to their
usual treatment, and can be considered as a viable option.
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